Clinical trials: Diabetic Nephropathy
Diabetic Kidney Disease
To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation
To evaluate the efficacy of probiotics in the treatment of diabetic kidney disease, this study is designed to explore after consumption of probiotics lactobacillus reuteri ADR-1 and lactobacillus rhamnosus GM-020 composite strain…
- Trial name
- NCT05674981
- Testing
- Probiotic group
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- GenMont Biotech Incorporation
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
- Trial name
- NCT01053936
- Testing
- Bardoxolone methyl (amorphous dispersion)
- Where
- 26 sites in United States
- Volunteers
- 129 people
- Sponsor
- Biogen
Diabetes Type 2
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.
- Trial name
- NCT00464880
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Novartis
Diabetic Nephropathies, Peripheral Nervous System Diseases
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects.
- Trial name
- NCT02552277
- Testing
- PDA-002
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Celularity Incorporated
Anemia
A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
This single arm, open label study will assess the efficacy, safety and tolerability of methoxy polyethylene glycol-epoetin beta for the treatment of chronic renal anemia in participants with chronic kidney disease (CKD) secondary…
- Trial name
- NCT01191983
- Testing
- Methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 14 sites in India
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Arteriovenous Fistula Stenosis
Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease
A Study on the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis
- Trial name
- NCT07452822
- Testing
- Human umbilical cord mesenchymal stem cells injection, saline solution
- Volunteers
- 54 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Diabetic Nephropathy
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Prospective, randomized, double-blind, placebo controlled, 12-week, multicenter study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets compared to placebo in…
- Trial name
- NCT01424319
- Testing
- Atrasentan low dose group, Atrasentan high dose group
- Where
- 18 sites in Japan
- Volunteers
- 58 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Diabetic Kidney Disease (DKD)
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
- Trial name
- PROMISS-DKD (NCT06962098)
- Testing
- Isuzinaxib
- Where
- 20 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetic Nephropathies
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting microalbuminuria associated with…
- Trial name
- NCT00153088
- Testing
- Telmisartan capsule 40 mg, Telmisartan capsule 80 mg
- Where
- 160 sites in Japan
- Volunteers
- 527 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease, CAKUT
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
- Conditions
- Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
- Trial name
- NCT05694169
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Prokidney
Diabetic Nephropathy
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting…
- Trial name
- NCT03804879
- Testing
- Nidufexor, Standard of Care (SoC)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first morning void urine sample as an indicator.
- Trial name
- NCT02517320
- Testing
- MT-3995 Low, MT-3995 Middle, MT-3995 High
- Where
- Japan
- Volunteers
- 293 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Type 2 Diabetes Mellitus With Diabetic Nephropathy
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
- Trial name
- NCT03217591
- Testing
- IW-1973
- Where
- 54 sites in United States
- Volunteers
- 156 people
- Sponsor
- Akebia Therapeutics
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Type 2 Diabetic Nephropathy
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)
- Trial name
- NCT06606093
- Testing
- DWP16001 0.3mg
- Where
- South Korea
- Volunteers
- 348 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Chronic Kidney Disease, Type 2 Diabetes
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when this compound is administered once daily for…
- Trial name
- NCT02316821
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 216 people
- Sponsor
- Kyowa Kirin Co., Ltd.